---
title: "Synthetic biology concept stocks strengthen, SHENGDA BIO-PHARM hits the daily limit in the afternoon"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235355324.md"
description: "On April 10th, synthetic biology concept stocks strengthened. As of 14:23, SHENGDA BIO-PHARM hit the daily limit, Sanyuan Biotechnology, BLB, SC Pharmaceuticals, and Kingdomway had previously hit the daily limit, while Jinbo Biotechnology and Wuxi Jinghai rose over 10%"
datetime: "2025-04-10T06:27:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235355324.md)
  - [en](https://longbridge.com/en/news/235355324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235355324.md)
generator: "portal-rs"
---

# Synthetic biology concept stocks strengthen, SHENGDA BIO-PHARM hits the daily limit in the afternoon

On April 10th, synthetic biology concept stocks strengthened. As of 14:23, SHENGDA BIO-PHARM hit the daily limit, Sanyuan Biotechnology, BLB, SC Pharmaceuticals, and Kingdomway had previously hit the daily limit, while Jinbo Biology and Wuxi Jinghai rose over 10%

### Related Stocks

- [603079.CN](https://longbridge.com/en/quote/603079.CN.md)
- [301206.CN](https://longbridge.com/en/quote/301206.CN.md)
- [002286.CN](https://longbridge.com/en/quote/002286.CN.md)
- [002693.CN](https://longbridge.com/en/quote/002693.CN.md)
- [002626.CN](https://longbridge.com/en/quote/002626.CN.md)

## Related News & Research

- [Odfjell Technology (OB:OTL) Stock Faces A Bigger Margin Question](https://longbridge.com/en/news/296647267.md)
- [Nasdaq Futures Plunge as Rising Bond Yields Drive Chip Selloff](https://longbridge.com/en/news/296216952.md)
- [Orkla Non-GAAP EPS of NOK 1.60, revenue of NOK 16.7B](https://longbridge.com/en/news/296456178.md)
- [Zaptec insider-linked company buys shares worth NOK 12.36 million](https://longbridge.com/en/news/296378460.md)
- [10:25 ETWatercrest Winter Park Awarded Best Assisted Living and Best Memory Care Community in Central Florida Survey](https://longbridge.com/en/news/296506259.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**